2. Academic Validation
  3. Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor

Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor

  • Biochem Pharmacol. 2014 Apr 1;88(3):313-21. doi: 10.1016/j.bcp.2014.01.034.
Magdalena M Bajer 1,  Michael M Kunze 1,  Johanna S Blees 1,  Heidi R Bokesch 2,  Hanyong Chen 3,  Thilo F Brauss 1,  Zigang Dong 3,  Kirk R Gustafson 4,  Ricardo M Biondi 5,  Curtis J Henrich 2,  James B McMahon 4,  Nancy H Colburn 6,  Tobias Schmid 7,  Bernhard Brüne 1
Affiliations

Affiliations

  • 1 Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, 60590 Frankfurt, Germany.
  • 2 Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, MD 21702, USA; Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
  • 3 The Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
  • 4 Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, MD 21702, USA.
  • 5 Research Group PhosphoSites, Department of Internal Medicine I, University Clinic, 60590 Frankfurt, Germany.
  • 6 Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, MD 21702, USA.
  • 7 Institute of Biochemistry I, Faculty of Medicine, Goethe-University Frankfurt, 60590 Frankfurt, Germany. Electronic address: t.schmid@biochem.uni-frankfurt.de.
PMID: 24513322 DOI: 10.1016/j.bcp.2014.01.034
Abstract

Deregulation of the phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR)-70kDa ribosomal protein S6 kinase 1 (p70(S6K)) pathway is commonly observed in many tumors. This pathway controls proliferation, survival, and translation, and its overactivation is associated with poor prognosis for tumor-associated survival. Current efforts focus on the development of novel inhibitors of this pathway. In a cell-based high-throughput screening assay of 15,272 pure natural compounds, we identified pomiferin triacetate as a potent stabilizer of the tumor suppressor programmed cell death 4 (Pdcd4). Mechanistically, pomiferin triacetate appeared as a general inhibitor of the PI3K-Akt-mTOR-p70(S6K) cascade. Interference with this pathway occurred downstream of Akt but upstream of p70(S6K). Specifically, mTOR kinase emerged as the molecular target of pomiferin triacetate, with similar activities against mTOR complexes 1 and 2. In an in vitro mTOR kinase assay pomiferin triacetate dose-dependently inhibited mTOR with an IC50 of 6.2 μM. Molecular docking studies supported the interaction of the inhibitor with the catalytic site of mTOR. Importantly, pomiferin triacetate appeared to be highly selective for mTOR compared to a panel of 17 lipid and 50 protein kinases tested. As a consequence of the mTOR inhibition, pomiferin triacetate efficiently attenuated translation. In summary, pomiferin triacetate emerged as a novel and highly specific mTOR Inhibitor with strong translation inhibitory effects. Thus, it might be an interesting lead structure for the development of mTOR- and translation-targeted anti-tumor therapies.

Keywords

Mammalian target of rapamycin; Natural product; Pomiferin triacetate; Translation.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z